Italian Welfare UndersecretaryFerruccio Fazio disapproves of private biobanks and is clearly in favor of the “allogenic” conservation of umbilical cord stem cells, meaning the conservation of stem cells saved for the exclusive use of the donor-patient. Speaking about a government report on “the appropriate use of umbilical cord stem cells”, Fazio outlined the government’s approach on the issue. A few weeks after a ministerial decree dictating new regulations for umbilical cord conservation, Fazio explained autologous donation, meaning conservation of stem cells for yourself, “is not only less useful, but also less efficient as science has demonstrated”.
The only exception allowed by the ministerial decree is “the conservation of umbilical cord blood to be used by families with children who are at risk for diseases that are genetically determined, which are scientifically proven and clinically approved to be treated with umbilical cord stem cells upon presenting clinical documentation released by a specialist”. From a scientific standpoint, underlined Fazio, “the use of hematopoietic stem cells for allogenic transplants creates another advantage because these stem cells eliminate diseased cells that remain after chemotherapy or radiotherapy, thanks the ability of special white blood cells from the donor to recognize them as foreign and destroy the residual diseased cells, performing an actual ‘cellular therapy’. This effect of hematopoietic stem cells transplants is known as ‘Graft versus Leukemia’. Continue reading →
DURHAM — To donate the stem cell-rich umbilical cord blood produced during the birth of her daughter, Jaime Feaster of Lake Charles, La., would have had to drive more than two hours to the nearest hospital equipped to collect it.
That’s a long way to go when you’re in labor.
Instead, Feaster turned to a fledgling Duke University Medical Center program that provides collection kits to mothers and their doctors. When Feaster’s daughter, Kadee, arrived last month, the cord blood was collected, packaged and quickly shipped to a blood bank at no cost to Feaster and with minimal commitment of time and expertise from her doctor.
Duke doctor Joanne Kurtzberg wants to replicate Feaster’s experience on a large scale.
Kurtzberg hopes that an easier donation process will trigger a surge in donations of blood cells so valuable they’ve been used to reverse and even cure otherwise fatal disorders. The current cord blood supply can’t keep up with the demand for its use in treating leukemia, sickle cell disease and other blood disorders, and the nation’s hospital infrastructure isn’t set up to tap even a fraction of the potential donors.
New research has found that stem cells derived from human cord blood could be an effective alternative in repairing heart attacks.
At least 20 million people survive heart attacks and strokes every year, according to World Health Organisation estimates, but many have poor life expectancy and require continual costly clinical care. The use of patient’s own stem cells may repair heart attacks, although their benefit may be limited due to scarce availability and ageing. The researchers have found heart muscle-like cells grown using stem cells from human umbilical cord blood could help repair heart muscle cells damaged by a heart attack.
The findings could have major implications on future treatment following a heart attack given that cells obtained from adults following a heart attack may be less functional due to ageing and risk factors.
Professor Ascione said: “We believe our study represents a significant advancement and overcomes the technical hurdle of deriving cardiac muscle-type cells from human cord blood. The method we have found has the attributes of simplicity and consistency. This will permit more robust manipulation of these cells towards better cell homing and cardiac repair in patients with myocardial infarction.
Sutter Neuroscience Institute in Sacramento, California, and Cord Blood Registry are launching the first FDA-regulated clinical trial to assess the use of a child’s own cord bloodstem cells to treat select patients with autism. This first-of-its-kind placebo-controlled study is important because one in 88 children in the U.S. are diagnosed with autism spectrum disorders each year. The clinical trial will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior.
The study will enroll 30 children between the ages of two and seven, who meet the inclusion criteria for the study. Enrolled participants will receive two infusions—one of the child’s own cord blood stem cells and one of a placebo—over the course of 13 months. Both the participants and the lead investigators will be blinded from knowing the content of each infusion. To ensure consistency in cord blood stem cell quality, CBR is the only family stem cell bank providing units from clients for the study. If you would like to be contacted regarding trial participation, please sign up here.
Corey de Gregorio, a 3 year old boy from Gordonvale, Australia has improved tremendously after going to a Stem Cell research company which implanted Adult Stem Cells from cord blood into him.
Corey’s parents, Mark and Roseanne had doubts before going to China for the stem cell treatment, but they wanted Corey to have every chance to live a better life and therefore, they made the journey to China for the stem cell therapy which used only Adult Stem Cells.
The miracle treatment consisted of six “therapies” of cord blood stem cells.
Before the Adult Stem Cells for Cerebral Palsy
Had very little use of his left arm/hand
Little movement in his torso
After the Stem Cell Treatment
Can now use his left hand, can use it to drink a cup by himself
cerebral palsy and adulthood, implications of soft tissue release in cerebral palsy, stem cell research for cerebral palsy, stem cells for cerebral palsy, treatment for cerebral palsy adults in binghamton.